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ACIP recommends annual influenza 
vaccination for all people ages 6 months 
and older.  To read the provisional 
influenza vaccination recommendations, 
click here. 
 
CDC encourages providers to 
begin offering influenza vaccine to 
people of all ages as soon as it 
becomes available (usually mid-to-
late summer).  Note: Early 
vaccination of children younger 
than age 9 years who are first-time 
vaccinees (or who failed to get 
their second dose in the preceding 
season) can be helpful in assuring 
there is adequate time to receive 
routine second doses before the 
influenza season begins.  
 
On April 30, 2010, CDC published 
ACIP's guidance for use of a high-dose 
injectable inactivated trivalent influenza 
vaccine (Fluzone High-Dose; Sanofi 
Pasteur).  The vaccine, 
which will be available for the 
2010-11 influenza season, 
was licensed as a single 
dose for use in people age 
65 years and older by the 
FDA in December 2009.   
 
ACIP has not expressed a 
preference for Fluzone High-
Dose or any specific licensed 
inactivated trivalent influenza 
vaccine for use in people 
age 65 years and older. To 
access the ACIP guidance 
for use of Fluzone High-Dose, click here. 
 
unization Program
Iowa Immunization Law Changes 
Effective May 12, 2010, Chapter 7 of the Iowa 
Immunization Law was updated to reflect 
revised ACIP recommendations on Polio 
vaccine.   
 
This change affects children born after 
September 15, 2003, who have received 3 
doses of Polio vaccine with the 3rd dose 
administered on or after the 4th birthday.  These 
children have been age appropriately 
vaccinated and are in compliance with Iowa 
immunization law (footnote number 5 on the 
requirements chart).   
 
It is important to review the footnotes of the 
Immunization Requirements chart when 
evaluating if a child meets Iowa Immunization 
Law.  The Immunization Requirements chart 
appears on page 6 of this newsletter.   
 
If you have questions about Iowa’s Immunization Law contact Terri Thornton, Nurse 
Consultant, at 800-831-6292, ext 2.  
1 
Many children in my practice 
have received their complete 
series of 7-valent pneumococcal 
conjugate vaccine (PCV7). 
Would you please review the 
recommendations for which of 
This also includes children who 
have previously received 
pneumococcal polysaccharide 
vaccine (PPSV23).  
 
The single supplemental dose of 
PCV13 should not be administered 
sooner than 8 weeks after the last 
dose of PCV7 or PPSV23 was 
given.  
Immunization Action Coalition has 
created a table that explains the use 
of PCV13 to catch up children who 
have fallen behind on their PCV7 
doses.  Click here to view.   
them now need a supplemental 
dose of 13-valent pneumococcal 
conjugate vaccine (PCV13)?  
 
A single supplemental dose of PCV13 
is recommended for all children ages 
14 through 59 months who have 
received the complete 4-dose series of 
PCV7 or another age-appropriate, 
complete PCV7 schedule.   
 
For children who have underlying 
medical conditions, a single 
supplemental PCV13 dose is 
recommended through age 71 months.  
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Question Corner  
New CDC Recommendations For the Use of MMRV Vaccine  
On May 7, 2010, CDC issued new 
recommendations for the use of 
combination MMRV vaccine.   
 
Prior to issuing these 
recommendations, ACIP reviewed 
results of post-licensure studies 
that suggest that, during the 5–12 
day post-vaccination 
period, approximately 
one additional febrile 
seizure occurred 
among every 2,600 
children ages 12 
through 23 months 
vaccinated with a first 
dose of MMRV 
vaccine, when 
compared with 
children in the same 
age group vaccinated 
with separate first 
doses of MMR 
vaccine and varicella 
vaccine administered 
during a single office 
visit.  
 
The summary of the 
recommendations for 
use of MMRV vaccine are as 
follows:  
 The routinely recommended 
ages for measles, mumps, 
rubella, and varicella 
vaccination continue to be age 
12 through 15 months for the 
first dose and age 4 through 6 
years for the second dose.  
 For the first dose of measles, 
mumps, rubella, and varicella 
vaccines at age 12 through 47 
months, providers may use 
either MMR 
vaccine and 
varicella 
vaccine or 
MMRV 
vaccine. 
Providers who 
are 
considering 
administering 
MMRV 
vaccine should 
discuss the 
benefits and 
risks of both 
vaccination 
options with 
the parents or 
caregivers. 
Unless the 
parent or 
caregiver 
expresses a preference for 
MMRV vaccine, CDC 
recommends that providers 
administer MMR vaccine and 
varicella vaccine for the first 
dose in this age group.  
 For the second dose of measles, 
mumps, rubella, and varicella 
vaccines at any age (15 months 
through 12 years) and for the 
first dose at age 48 months and 
older, use of MMRV vaccine 
generally is preferred over 
separate injections of its 
equivalent component vaccines 
(i.e., MMR vaccine and varicella 
vaccine).  
 A personal or family (i.e., sibling 
or parent) history of seizures of 
any etiology (i.e., cause) is a 
precaution for MMRV 
vaccination, and such children 
generally should be vaccinated 
with MMR vaccine and varicella 
vaccine.  
 
The complete recommendations for 
the use of MMRV vaccine are 
available  by clicking here.  
In addition, CDC has issued a new 
VIS for MMRV vaccine, dated 
5/21/10, which is available by clicking 
here.  As with all other VISs, parent or 
vaccine recipient should be given the 
VIS prior to vaccination to facilitate 
discussion about the vaccine between 
the patient and provider.  
Unless the parent or caregiver 
expresses a preference for MMRV 
vaccine, CDC recommends that 
providers administer MMR vaccine 
and varicella vaccine for the first dose 
in this age group (12-47 months).  
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FDA Approves Resuming Use of Rotarix Vaccine 
infection or illness in humans. For 
additional information on this topic 
click here. 
 
On May 14, 2010, CDC published a 
revised interim VIS for the use of 
rotavirus vaccine.  The new VIS 
includes the following information: 
"A virus (or parts of the virus) called 
porcine circovirus is in both rotavirus 
vaccines. This virus is not known to 
infect people and there is no known 
safety risk.”  
 
For more information, see 
www.fda.gov. or to access the VIS 
click here.  
On May 14, 2010, the FDA issued 
updated recommendations for using 
rotavirus vaccine, announcing that 
clinicians can resume using Rotarix 
vaccine (RV1; GSK) and continue 
using RotaTeq vaccine (RV5; Merck).  
 
Previously, on March 22, 2010, the 
FDA had recommended that U.S. 
clinicians and public health 
professionals temporarily suspend 
use of Rotarix while the FDA and 
GSK investigated the finding of DNA 
from porcine circovirus type 1 (PCV1) 
in the vaccine.  The FDA and GSK 
have since confirmed the presence of 
PCV1 in the vaccine.   
 
On May 6, 2010, the FDA indicated 
that Merck's preliminary studies of 
RotaTeq had identified fragments of 
DNA from PCV1 and from a related 
porcine circovirus type 2 (PCV2) in 
RotaTeq.  
 
The FDA has evaluated laboratory 
results from the manufacturers and 
its own laboratories. Based on a 
careful evaluation of this information, 
a thorough review of the scientific 
literature, and input from scientific 
and public health experts, the FDA 
announced that clinicians can 
resume using Rotarix and 
continue using RotaTeq.   
 
The FDA noted that it there is no 
evidence that either PCV1 or PCV2 
poses a safety risk in humans and 
that neither is known to cause 
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System (IRIS).  If doses 
administered data, which relates to 
vaccine inventory, are not 
appropriately accounted for, orders 
for VFC vaccine may be reduced.   
 
Prior to placing vaccine orders it is 
important to assure IRIS data entry is 
up to date (doses administered 
entered as a “Give”) or doses 
administered reports have been 
submitted to the VFC Program and 
assure that IRIS vaccine inventory 
matches refrigerator/freezer 
inventory on a monthly basis.   
 
VFC Vaccine Accountability  
The National Vaccines for Children 
(VFC) Program has grown to be 
more than a $3 billion annual 
program.  With such a large 
program there is significant need for 
accountability to prevent vaccine 
fraud and abuse.   
 
One of the Iowa’s VFC Program’s 
means of vaccine accounting is 
doses administered reporting.  It is 
critically important for all VFC 
Program providers to submit 
monthly doses administered reports 
or enter doses administered into the 
Immunization Registry Information 
The CDC is closely monitoring the 
number of vaccine orders placed for 
each state.  Iowa VFC Program 
providers should not place vaccine 
orders more than once a month.  
Placing vaccine orders more 
frequently leads to increased cost to 
fulfill orders and to distribute the 
orders to health care providers.   
 
If you have any questions regarding 
reductions in your vaccine order 
please contact Tina Patterson at 800-
831-6293, ext 4. 
 
Currently there are more than 2.3 
million records in the Immunization 
Registry Information System (IRIS).  
The most effective way to search for 
a patient’s record is by the patient’s 
date of birth which eliminates the 
possibility of misspelled names or 
nicknames.  If the desired patient is 
not found, search instead by a few 
letters of the first and last name 
without a date of birth.  Searching 
for patient records with less 
information will produce more 
matching records.  This list will 
allow you to be sure the correct 
patient record is open and 
immunizations are documented 
properly.       
 
IRIS staff routinely identify and 
resolve duplicate records in IRIS.  If 
duplicate records are discovered, 
update only one of the records with 
the immunizations you are giving.  If 
discrepancies are found, such as 
misspelled names or incorrect date 
of birth, make the necessary 
corrections to the record and report 
the duplicate record to the IRIS 
Help Desk.  
When 
contacting 
the IRIS 
Help Desk 
include the 
patient’s 
last name, 
first name, 
and date of 
birth.   
 
If you have 
questions regarding IRIS, contact 
the Help Desk at 800-374-3958.  
IRIS Tip: How to effectively search for patient records 
On May 28, 2010, CDC published 
updated recommendations for 
human papillomavirus (HPV) 
vaccination of females with bivalent 
HPV vaccine (HPV2; Cervarix; 
GSK) and quadrivalent HPV 
vaccine (HPV4; Gardasil; Merck).   
 
Routine vaccination with 3 doses of 
either HPV2 or HPV4 is 
recommended for females ages 11 
or 12 years and can be started in 
females as young as 9 years of age.  
Vaccination is recommended for 
females ages 13 through 26 years 
who have not been vaccinated 
previously or who have not 
completed the 3-dose series.  If a 
female reaches age 26 years before 
the vaccination series is complete, 
remaining doses can be 
administered after age 26 years.   
 
Ideally, vaccine should be 
administered before potential 
exposure to HPV through sexual 
contact.  To access the updated 
recommendations, click here  and 
see pages 626-629.  
 
 On May 28, 2010, CDC published 
guidance for human papillomavirus 
(HPV) vaccination of males with 
quadrivalent HPV vaccine (HPV4; 
Gardasil; Mer-ck).  The 3-dose 
series of HPV4 may be given to 
males age 9 through 26 years to 
reduce their likelihood of acquiring 
genital warts. HPV4 would be most 
effective when given before 
exposure to HPV through sexual 
contact. To access CDC’s guidance 
click here. 
Updated HPV Recommendations  
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Common Myth:  If the thermometer shows a temperature reading outside the recommended range something must 
be wrong with the thermometer. 
 
Fact:  If a temperature reading is outside the recommended range, the thermometer should be assumed to be correct 
until proven otherwise.  Check your back up thermometer.  Always take immediate action when temperatures are out 
of range and document your actions. Click here to view IDPH Trouble Shooting Log.  
 
Type 
 There are several types of thermometers you can use.  Vaccines are expensive.  It is important to invest in 
the best thermometer you can afford and understand how to use it.  
 Use only certified calibrated thermometers for measuring vaccine storage unit temperatures.  All 
thermometers are calibrated during manufacturing, meaning they are given a temperature scale.  Certified 
calibrated thermometers undergo a second individual calibration against a reference standard from an 
appropriate agency, such as the National Institute of Standards and Technology (NIST). 
 
Maintenance 
 Certified calibrated thermometers require periodic recertification and recalibration against reference 
thermometers in order to remain accurate.  The Iowa Department of Public Health, Immunization Program 
recommends adhering to the recalibration schedule recommended by the manufacture.. 
 If the thermometer is electronic, change the battery on a regular basis. 
 To prevent wire breakage in the probe cord consider coiling some of the cord inside the storage unit and 
some on the outside and taping the part that passes between the door flush with the surface. 
 Consider placing the thermometer on top of the unit rather than relying on the magnet or Velcro to hold it in 
place on the front on the unit.  This will help avoid those accidental drops that can damage a thermometer. 
 
 Use 
 Temperatures need to be documented twice each day, when the clinic opens and again at the end of the day.  
This recommendation applies regardless of whether or not there is a temperature alarm, a chart recorder 
thermometer, or a digital data logger. 
 The thermometer should be placed in the center of the storage compartment, adjacent to the vaccine, away 
from the coils, walls, floor, and fan in order to obtain a true reading of the temperature. 
 In the refrigerator, the thermometer should be placed on the middle shelf, or hanging down from the upper 
shelf. 
 In the freezer, the thermometer should be suspended from the ceiling of the compartment or placed on a box 
or some other item that is in the middle of the compartment off the floor. 
 A backup thermometer should also be in each storage unit. 
 
Click the links in orange o access IDPH temperature logs (Fahrenheit / Celsius).    If you have questions regarding 
thermometers, please contact Terri Thornton, Nurse Consultant, at 800-831-6292, ext 2.  
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Stay Up-to-Date on the Latest Immunization 
Changes and Challenges 
 
CDC is offering several new training courses for immunization providers. A 
self-study course focusing on Adult Immunization was released June 15, 2010.  
 
The annual Epidemiology and Prevention of Vaccine-Preventable Diseases 
has just been released and it has been expanded to nine self-study modules 
and is now available on DVD or in web-on-demand format. To order one free 
copy of the DVD using the NCIRD ordering system, click here and then scroll 
down to item #22-0068.  
IMMUNIZATION REQUIREMENTS  
Applicants enrolled or attempting to enroll shall have received the following vaccines in accordance with the doses and age requirements listed below. If, at any time, the age of the child is 
between the listed ages, the child must have received the number of doses in the “Total Doses Required” column.   
Institution Age Vaccine Total Doses Required 
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Less than 4 
months of age 
This is not a recommended administration schedule, but contains the minimum requirements for participation in licensed child care.  Routine vaccination 
begins at 2 months of age.   
   
4 months 
through 5 
months of age 
Diphtheria/Tetanus/Pertussis 1 dose 
Polio 1 dose 
haemophilus influenzae type B 1 dose 
Pneumococcal 1 dose 
   
6 months 
through 11 
months of age 
Diphtheria/Tetanus/Pertussis 2 doses 
Polio 2 doses 
haemophilus influenzae type B 2 doses  
Pneumococcal 2 doses 
   
12 months 
through 18 
months of age 
Diphtheria/Tetanus/Pertussis 3 doses 
Polio 2 doses 
haemophilus influenzae type B 
2 doses; or  
1 dose received when the applicant is 15 months of age or older. 
Pneumococcal 
3 doses if the applicant received 1 or 2 doses before 12 months of age; or 
2 doses if the applicant has not received any previous doses or has received 1 dose on or after 12 months of age. 
   
19 months 
through 23 
months of age 
Diphtheria/Tetanus/Pertussis 4 doses 
Polio 3 doses 
haemophilus influenzae type B 
3 doses, with the final dose in the series received on or after 12 months of age, or 1 dose received when the applicant is 15 
months of age or older. 
Pneumococcal 
4 doses; or  
3 doses if the applicant received 1 or 2 doses before 12 months of age; or  
2 doses if the applicant has not received any previous doses or has received 1 dose on or after 12 months of age. 
Measles/Rubella1 
1 dose of measles/rubella-containing vaccine received on or after 12 months of age; or the applicant demonstrates a 
positive antibody test for measles and rubella from a U.S. laboratory.  
Varicella 
1 dose received on or after 12 months of age if the applicant was born on or after September 15, 1997, unless the applicant 
has had a reliable history of natural disease.   
   
24 months 
and older 
Diphtheria/Tetanus/Pertussis 4 doses 
Polio 3 doses 
haemophilus influenzae type B 
3 doses, with the final dose in the series received on or after 12 months of age; or 1 dose received when the applicant is 15 
months of age or older.  Hib vaccine is not indicated for persons 60 months of age or older. 
Pneumococcal 
4 doses if the applicant received 3 doses before 12 months of age; or  
3 doses if the applicant received 2 doses before 12 months of age; or  
2 doses if the applicant received 1 dose before 12 months of age or received 1 dose between 12 and 23 months of age; or  
1 dose if no doses had been received prior to 24 months of age. 
Pneumococcal vaccine is not indicated for persons 60 months of age or older.  
Measles/Rubella1 
1 dose of measles/rubella-containing vaccine received on or after 12 months of age; or the applicant demonstrates a 
positive antibody test for measles and rubella from a U.S. laboratory. 
Varicella 
1 dose received on or after 12 months of age if the applicant was born on or after September 15, 1997, unless the applicant 
has had a reliable history of natural disease.   
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4 years of age 
and older 
Diphtheria/Tetanus/ 
Pertussis 3, 4  
3 doses, with at least 1 dose of diphtheria/tetanus/pertussis-containing vaccine received on or after 4 years of age if the 
applicant was born on or before September 15, 2000; or  
4 doses, with at least 1 dose of diphtheria/tetanus/pertussis-containing vaccine received on or after 4 years of age if the 
applicant was born after September 15, 2000, but before September 15, 2003; or  
5 doses with at least 1 dose of diphtheria/tetanus/pertussis-containing vaccine received on or after 4 years of age if the 
applicant was born on or after September 15, 2003.2 
DTaP is not indicated for persons 7 years of age and older, therefore, a tetanus-and diphtheria-containing vaccine should 
be used.  
Polio 6 
3 doses, with at least 1 dose received on or after 4 years of age if the applicant was born on or before September 15, 2003; 
or 
4 doses, with at least 1 dose received on or after 4 years of age if the applicant was born after September 15, 2003.5 
Measles/Rubella1 
2 doses of measles/rubella-containing vaccine; the first dose shall have been received on or after 12 months of age; the 
second dose shall have been received no less than 28 days after the first dose; or the applicant demonstrates a positive 
antibody test for measles and rubella from a U.S. laboratory.  
Hepatitis B 3 doses if the applicant was born on or after July 1, 1994. 
Varicella 
1 dose received on or after 12 months of age if the applicant was born on or after September 15, 1997, but born before 
September 15, 2003, unless the applicant has had a reliable history of natural disease; or 
2 doses received on or after 12 months of age if the applicant was born on or after September 15, 2003, unless the 
applicant has a reliable history of natural disease.7 
1 Mumps vaccine may be included in measles/rubella-containing vaccine. 
2 The 5th dose of DTaP is not necessary if the 4th dose was administered on or after 4 years of age.  
3 Applicants 7 through 18 years of age who received their 1st dose of diphtheria/tetanus/pertussis-containing vaccine before 12 months of age should receive a total of 4 doses, with one of those doses administered on or after 4 years of 
age.    
4 Applicants 7 through 18 years of age who received their 1st dose of diphtheria/tetanus/pertussis-containing vaccine at 12 months of age or older should receive a total of 3 doses, with one of those doses administered on or after 4 years 
of age.   
5 If an applicant received an all-inactivated poliovirus (IPV) or all-oral poliovirus (OPV) series, a 4th dose is not necessary if the 3rd dose was administered on or after 4 years of age.    
6 If both OPV and IPV were administered as part of the series, a total of 4 doses are required, regardless of the applicant’s current age. 
7 Administer 2 doses of varicella vaccine, at least 3 months apart, to applicants less than 13 years of age.  Do not repeat the 2nd dose if administered 28 days or greater from the 1st dose.  Administer 2 doses of varicella vaccine to 
applicants 13 years of age or older at least 4-weeks apart. The minimum interval between the 1st and 2nd dose of varicella for an applicant 13 years of age or older is 28 days. 
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